NCT07365410

Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study

Furmonertinib 160mg Versus Furmonertinib 80mg Combined With Chemotherapy (Carboplatin + Pemetrexed) as First-Line Treatment for EGFR-Mutated NSCLC Patients With Brain Metastases: A Multicenter Study of Efficacy and Safety

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Tianjin Medical University Cancer Institute and Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This multicenter study evaluates the efficacy and safety of furmonertinib 160mg versus furmonertinib 80mg plus chemotherapy (carboplatin + pemetrexed) as first-line treatment for EGFR-mutated NSCLC patients with brain metastases. It aims to determine which approach is more effective and safer.

Conditions

• Non-small Cell Lung Cancer (NSCLC)
• Brain Metastases
• Furmonertinib
• EGFR Mutation

Interventions

Type	Name	Description
DRUG	Furmonertinib	Oral administration, 160mg once daily.
DRUG	Furmonertinib	Oral administration, 80mg once daily
DRUG	carboplatin	Intravenous infusion, cycle-based (per study protocol).
DRUG	pemetrexed	Intravenous infusion, cycle-based (per study protocol).

Timeline

• Start date: 2026-01-01
• Primary completion: 2026-05-01
• Completion: 2028-12-01
• First posted: 2026-01-26
• Last updated: 2026-01-26

Locations

1 site across 1 country: China